Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology

blog.png
September 21, 2017 Blood Cancer PDX Models: Focus on Acute Myeloid Leukemia‎ A number of our previous posts have covered the benefits of patient-derived xenografts (PDX), usually focusing on models derived from solid tumors. But these highly predictive preclinical models can also be developed from blood cancer. LEARN MORE
September 19, 2017 Beginners Guide: Humanized Drug Target Immuno-Oncology Models Our recent post compared stable vs transiently humanized models, which are needed when human-specific therapeutics are ... LEARN MORE
September 12, 2017 CD137: An Important Target in T Cell Co-Stimulation Following on from OX40, our TNF superfamily posts continue with CD137, another important target in T cell ... LEARN MORE
September 7, 2017 When to Use Stable vs Transiently Humanized I/O Models As immunotherapeutics continue to dominate oncology headlines and research, more preclinical studies are requiring ... LEARN MORE
September 5, 2017 Treatment Approaches for EGFR-Mutated Lung Cancer Each year, around 140,000 people worldwide (15,000 in the United States alone) are diagnosed with epidermal growth ... LEARN MORE
August 29, 2017 OX40 Agonists: Boosting Cancer Immunotherapy Following our recent post covering the Tumor Necrosis Factor Superfamily of Ligands and Receptors, we’re going to take ... LEARN MORE
August 24, 2017 Mouse Allograft Models: A GEMM-Derived Efficacy Testing Platform Genetically engineered mouse models (GEMM) were reviewed in a recent post, as immunocompetent, murine immunity models for immuno-oncology assays. While highly useful for monitoring cancer progression and mechanism of action studies, the spontaneous nature of GEMM tumors makes them complex and costly models for efficacy studies. LEARN MORE
August 22, 2017 The Beginners Guide to Neoantigens and Immuno-Oncology Studies \Neoantigens are mutation associated antigens that arise from nonsynonomous somatic variations acquired in tumors ... LEARN MORE
August 15, 2017 Genetically Engineered Mouse Models (GEMM) for I/O Studies Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ... LEARN MORE
August 10, 2017 Tumor Necrosis Factor Superfamily of Ligands and Receptors 101 Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated ... LEARN MORE
August 8, 2017 Syngeneic Tumor Mouse Models: The Pros and Cons Immunotherapeutics are bringing remarkable survival rates for certain cancer patients, but they are also bringing some remarkable challenges for oncology drug developers. Evaluating immunomodulatory agents is more complex than assessing “common” chemotherapeutics or targeted agents. It requires preclinical models with an intact immune system (or at least ... LEARN MORE
August 3, 2017 How Patient Derived Tumor Grafts (PDX) Accelerate Early Drug Development × Over the year’s cancer research and drug development have moved from developing “simple” chemotherapies which stop ... LEARN MORE
July 25, 2017 Precision Medicine: First Multi-Agent Next-Generation Sequencing Companion Diagnostic Test Approved by the FDA Following our recent blog covering the first US FDA approval for a cancer treatment based on a biomarker regardless of ... LEARN MORE
July 20, 2017 Overcoming the Tumor Microenvironment and Heterogeneity to Improve Preclinical Response It is well known that the tumor microenvironment is quite complex to model preclinically. A major challenge we face is ... LEARN MORE
July 18, 2017 Overcoming Acquired Resistance with PDX Targeted therapies have been very successful in cancer treatment. Approved for a range of targets across many cancer ... LEARN MORE